Latest Quarterly Report
Filed: 2026-05-13
Key Insights
- Company filed Q1 2026 10-Q on May 13, 2026, indicating ongoing operations as a clinical-stage psychedelic medicine developer focused on psilocybin-assisted therapy for treatment-resistant depression.
- Multiple warrant issuances and equity offerings occurred in early 2026 (January-February underwritten offerings with ADS warrants and prefunded warrants), suggesting the company has been actively raising capital to fund operations and clinical development.
- Loan agreement was amended on January 5, 2026, with structured redemption periods outlined for Term Loan One, indicating debt management activities and potential refinancing or restructuring of existing facilities.
- Company maintains complex capital structure with ordinary shares, American Depositary Shares (ADS), multiple warrant classes, and various equity incentive plans, typical for biotech firms managing both UK and US market listings.